# Rejuvenate Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rejuvenate-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.rejuvenatebio.com/
- Total disclosed funding: $34M
- Latest round: Series B (Jun 3, 2026)
- Investors on record: 8

## About

Rejuvenate Bio Inc. is a biotechnology company focused on pioneering gene therapy solutions to combat chronic, age-related diseases, enhancing health and quality of life through advanced genetic editing technologies. Founded in 2019 by Daniel Oliver and Noah Davidsohn, Rejuvenate Bio Inc. is headquartered in San Diego, US. The company specializes in innovative gene therapy targeting chronic diseases. In June 2026, Rejuvenate Bio Inc. raised USD 19.4 million in series B funding from VCapital, Merck Animal Health Ventures, Jetstream Venture Fund, Kendall Capital Partners, Connecticut Innovations and Digitalis.

Rejuvenate Bio specializes in innovative gene therapy solutions aimed at addressing chronic, age-related diseases that affect a significant portion of the American population. Their core offerings encompass various human and animal health therapies designed to target the underlying genetic causes of these conditions. The company employs advanced gene editing technologies to develop therapies that not only alleviate symptoms but also aim for long-term health improvements, thereby enhancing the quality of life for individuals suffering from chronic diseases. These products are particularly relevant for healthcare providers seeking effective treatments for patients diagnosed with conditions such as diabetes and cardiovascular diseases. Rejuvenate Bio's products are marketed primarily within the United States, with potential expansion into international markets as the company grows. Rejuvenate Bio generates revenue through a combination of partnerships and direct sales of its gene therapy products. The company's revenue model includes engaging with healthcare providers and institutions that incorporate its therapies into their treatment protocols. Transactions typically involve negotiated contracts that outline specific pricing structures for different treatment regimens. The company's flagship products, which are designed to deliver targeted gene therapies, are sold on a per-treatment basis, creating a direct-to-consumer approach as well as B2B transactions with healthcare providers. This dual approach allows Rejuvenate Bio to cater to both individual patients seeking innovative treatments and larger healthcare systems looking to enhance their therapeutic offerings.

The funding will use the June 2026 funding to support development of the monoclonal antibody platform, achieve cash-flow positivity, and reduce need for future fundraising.

## Funding rounds

- Series B, Jun 3, 2026, $19M — Connecticut Innovations, Digitalis Ventures, VCapital, Merck Animal Health Ventures, Kendall Capital Partners, Jetstream Venture Fund
- Series A, Apr 13, 2021, $15M — Digitalis Ventures, KdT Ventures, Bat Capital, Kendall Capital Partners

## Investors

- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A, Series B
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Series A
- Bat Capital (https://capitalatlas.ai/funds/bat-capital) — Series A
- Kendall Capital Partners (https://capitalatlas.ai/funds/kendall-capital-partners) — Series A, Series B
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series B
- VCapital (https://capitalatlas.ai/funds/vcapital) — Series B
- Merck Animal Health Ventures (https://capitalatlas.ai/funds/merck-animal-health-ventures) — Series B
- Jetstream Venture Fund — Series B